Pages that link to "Q33497983"
Jump to navigation
Jump to search
The following pages link to Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis (Q33497983):
Displaying 17 items.
- Current stage in inflammatory bowel disease: What is next? (Q26777429) (← links)
- Have we overestimated the benefit of human(ized) antibodies? (Q34142714) (← links)
- Current and emerging drugs for the treatment of inflammatory bowel disease (Q34883210) (← links)
- Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study (Q37600224) (← links)
- T-cell-directed therapies in inflammatory bowel diseases. (Q37720783) (← links)
- Optimizing treatment and minimizing adverse events (Q37835705) (← links)
- Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations (Q37863515) (← links)
- The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. (Q38132555) (← links)
- Pathway-based approaches to the treatment of inflammatory bowel disease (Q38593257) (← links)
- Emerging treatments for ulcerative colitis: a systematic review. (Q39306383) (← links)
- Emerging drugs to treat Crohn's disease (Q39881787) (← links)
- Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice (Q42026744) (← links)
- Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. (Q43996419) (← links)
- Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection (Q50041876) (← links)
- Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH (Q57210121) (← links)
- Inflammatory cell infiltration in left atrial appendageal tissues of patients with atrial fibrillation and sinus rhythm (Q89518990) (← links)
- Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease? (Q90312722) (← links)